The next generation of allergy vaccines targeting dendritic cells

Inmunotek has brought a range of skills and scientific specialties together to create a vaccinebased approach for the treatment of allergies and other immune-based diseases.

Go to the profile of Inmunotek
Nov 06, 2018
0
0
Page of
Go to the profile of Inmunotek

Inmunotek

Pharmaceutical company based in Madrid, Spain. Founded in 1992, Inmunotek researches, develops, manufactures and markets diagnostics and therapeutics (vaccines) in the field of allergy and immunology. It has two GMP-facilities and R&D laboratories in Spain. Inmunotek employs 225 persons (2018), invests over 10% of its turnover in R&D projects and is included among the faster-growing companies in Europe. Inmunotek’s main interest is focused to therapeutic vaccines for allergy, recurrent infectious diseases and cancer. In the field of allergy, major developments include novel allergy vaccines targeting dendritic cells for both human and veterinary medicines. In the field of recurrent infections, major developments include mucosal (sublingual) bacterial vaccines targeting innate immunity for upper respiratory and urological (cystitis) infections. Cancer research is focused to the development of novel carbohydrate-based tumor vaccines. Inmunotek’s products are distributed worldwide in more than 50 countries.

No comments yet.